168 related articles for article (PubMed ID: 21981936)
1. Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.
Tanaka K; Ogawa Y; Shimada S
J Dermatol; 2012 Aug; 39(8):726-8. PubMed ID: 21981936
[No Abstract] [Full Text] [Related]
2. Sitagliptin intolerance.
Kargili A; Karakurt F; Kankilic MN; Kankilic ES; Bozkurtl B
Allergol Immunopathol (Madr); 2010; 38(5):290-1. PubMed ID: 20554368
[No Abstract] [Full Text] [Related]
3. Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.
Mas-Vidal A; Santos-Juanes J; Esteve-Martinez A; Caminal-Montero L; Coto-Segura P
Australas J Dermatol; 2012 Feb; 53(1):70-2. PubMed ID: 22309337
[TBL] [Abstract][Full Text] [Related]
4. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
5. [Sitagliptin].
Taéron C
Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
[No Abstract] [Full Text] [Related]
6. Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable.
Prescrire Int; 2009 Feb; 18(99):14-5. PubMed ID: 19391232
[TBL] [Abstract][Full Text] [Related]
7. Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®).
Stricklin SM; Stoecker WV; Rader RK; Hood AF; Litt JZ; Schuman TP
Dermatol Online J; 2012 Feb; 18(2):9. PubMed ID: 22398230
[TBL] [Abstract][Full Text] [Related]
8. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
Abel T; Fehér J
Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
[TBL] [Abstract][Full Text] [Related]
9. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Bailey CJ; Green BD; Flatt PR
Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
[TBL] [Abstract][Full Text] [Related]
10. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
Stafford S; Elahi D; Meneilly GS
J Am Geriatr Soc; 2011 Jun; 59(6):1148-9. PubMed ID: 21668924
[No Abstract] [Full Text] [Related]
11. Maculopapular-type drug eruption caused by sitagliptin phosphate hydrate: a case report and mini-review of the published work.
Nakai N; Katoh N
Allergol Int; 2014 Sep; 63(3):489-91. PubMed ID: 24957113
[No Abstract] [Full Text] [Related]
12. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports.
Desai S; Brinker A; Swann J; Iyasu S
Arch Intern Med; 2010 Jul; 170(13):1169-71. PubMed ID: 20625027
[No Abstract] [Full Text] [Related]
14. Elevated hepatic enzymes potentially associated with sitagliptin.
Gross BN; Cross LB; Foard J; Wood Y
Ann Pharmacother; 2010 Feb; 44(2):394-5. PubMed ID: 20103614
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
16. Drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient taking sitagliptin.
Sin C; Mahé E; Sigal ML
Diabetes Metab; 2012 Dec; 38(6):571-3. PubMed ID: 23183246
[TBL] [Abstract][Full Text] [Related]
17. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
Wright DH; Herman GA; Maes A; Liu Q; Johnson-Levonas AO; Wagner JA
J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
[TBL] [Abstract][Full Text] [Related]
18. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
19. [Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2013 Oct; 68(10):504-10. PubMed ID: 24298724
[TBL] [Abstract][Full Text] [Related]
20. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
Migoya EM; Stevens CH; Bergman AJ; Luo WL; Lasseter KC; Dilzer SC; Davies MJ; Wagner JA; Herman GA
Can J Clin Pharmacol; 2009; 16(1):e165-70. PubMed ID: 19221403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
